Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

DHT and 5-Alpha-Reductase

Dihydrotestosterone, the Potent Androgen Behind Hair Loss, Prostate Growth, and Skin Effects

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
5-alpha-reductase inhibitors FDA-approved for BPH (finasteride, dutasteride) and hair loss (finasteride; dutasteride is off-label for hair loss in the US), not for TRT management

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about dht and 5-alpha-reductase in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Dihydrotestosterone (DHT) is formed from testosterone by 5-alpha-reductase and binds the androgen receptor more potently than testosterone itself. It drives male-pattern hair loss, sebaceous activity (acne, oily skin), and prostate growth. 5-alpha-reductase inhibitors (finasteride, dutasteride) block its formation; both are FDA-approved for benign prostatic hyperplasia, and finasteride (1 mg) is FDA-approved for androgenetic alopecia, while dutasteride is used off-label for hair loss in the US.

The downstream androgen that does much of testosterone's work in skin, hair, and prostate.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Explaining hair loss and acne during testosterone therapy
  • Understanding finasteride/dutasteride for BPH and hair loss
  • Distinguishing DHT-mediated from estradiol-mediated effects

How it works

5-alpha-reductase exists in two main isoenzymes: type I (skin, liver) and type II (prostate, genital skin, hair follicles). Both reduce testosterone to DHT, which binds the androgen receptor with greater affinity and slower dissociation, amplifying androgenic signaling in those tissues. This explains why DHT, not testosterone, dominates prostate growth and follicular miniaturization. Finasteride inhibits type II; dutasteride inhibits both.

Why higher testosterone can mean more hair loss

Raising testosterone, therapeutically or supraphysiologically, increases substrate for DHT, which is why some men notice accelerated hair loss or acne on TRT. Blocking 5-alpha-reductase can blunt this but carries its own considerations (sexual side effects, mood reports with finasteride), and these agents are not a routine part of TRT.

Safety in detail

5-alpha-reductase inhibitors have documented sexual and mood side effects and require physician oversight. Changes to hormones, sexual function, or sexual health warrant evaluation by a qualified healthcare provider.

What it does to fertility

DHT itself is critical to male genital development; 5-alpha-reductase inhibitors can modestly affect semen parameters in some men. They do not replace gonadotropin-based fertility strategies and are not used to preserve fertility on TRT.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Symptom assessment (hair, skin, prostate) on testosterone therapy
  • PSA monitoring (5-alpha-reductase inhibitors lower PSA, affecting interpretation)

What people get wrong

  • Often saidDHT is just 'bad testosterone' that should always be blocked

    ActuallyDHT is essential to male sexual development and genital tissue; blocking it has trade-offs. 5-alpha-reductase inhibitors are indicated for specific conditions (BPH, hair loss), not as routine adjuncts to testosterone therapy.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Made from
Testosterone via 5-alpha-reductase
Potency
Higher AR affinity than testosterone
Targets
Hair follicles, prostate, skin
Blockers
Finasteride (type II), dutasteride (type I and II)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about DHT and 5-Alpha-Reductase. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Finasteride and dutasteride trials for BPH and alopecia1990s-2000s

    5-alpha-reductase inhibition reduces serum and tissue DHT, shrinks the prostate, and slows androgenetic hair loss, confirming DHT's central role in these androgen-driven processes